SOLICITATION NOTICE
Q -- Measure circulating hormone levels
- Notice Date
- 7/20/2012
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-12120-MD
- Archive Date
- 8/18/2012
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis with Laval University of 1045 Avenue de la Medecine, Quebec, QC G1V 0A6, Canada to measure circulating hormone levels. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 541380 and the business size standard is $14 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined that there is no opportunity to acquire Green Products or Services under this contract. The period of performance shall be twelve (12) months from date of award. Risk-reducing salpingoophorectomy is a highly effective means of reducing cancer risk among women at elevated risk for ovarian cancer. However, recent data from several cohorts suggest that oophorectomy may increase the risk of death among these women, especially if performed at early ages. Conversely, analyses in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) show that postmenopausal women with larger ovaries are at increased risk of breast and endometrial cancer. The postmenopausal ovaries along with the adrenals are the main source of androgens after menopause and serum androgen levels are both a risk factor for endometrial and ovarian cancer and a substrate for estrogen synthesis, which is also similarly related to risk. The purpose is to measure circulating hormone levels (including testosterone [T], androstenedione [4-dione], androstenediol [5-diol], dihydrotestosterone [DHT], androsterone [ADT] dehydroepiandrosterone (DHEA), estrone [E1], estradiol [E2], and sex-steroid-hormone binding globulin) at baseline in 575 serum samples. This analysis will be done using samples from the GOG 199 clinical trial, including 450 samples from 225 women who underwent oophorectomy, 100 serum samples from 50 women who did not undergo oophorectomy and 25 QC samples. In total, there will be 575 serum samples, each of at least 0.51 ml volume to be used for quantitation of the following nine (9) sex steroid hormones and protein: (1) Dehydroepiandrosterone (DHEA) using GC-MS, (2) Androstenediol (5-diol) using GC-MS, (3) Androstenedione (4-dione) using GC-MS, (4) Testosterone (T) using GC-MS, (5) Dihydrotestosterone (DHT) using GC-MS, (6) Androsterone (ADT) using GC-MS, (7) Estrone (E1) using GC-MS, (8) Estradiol (E2) using GC-MS, and Sex Hormone Binding Globulin (SHBG; protein) using ELISA. Laval University is the only known laboratory that can quantitate these 9 sex steroid hormones and SHBG using gold standard technologies (GC-MS for each hormone analyte, and ELISA for SHBG) using a total volume of just 0.51 ml of serum per patient, with coefficients of variations less than 10% and intra-class correlation coefficients of >90% for each analyte. Therefore, Laval University is the only known source available to NCI to complete this requirement. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 03, 2012. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120120-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-12120-MD/listing.html)
- Record
- SN02810337-W 20120722/120720235412-9c84f1c5d8f97be4173c2c0c3d228be6 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |